In addition, it has been recently reported [35] that allogeneic, donor-derived CD19 CAR cytokine induced killer (CIK) cells engineered with the SB system demonstrated high expansion, low toxicity, and complete remission in patients with relapsed and refractory ALL in a Phase-I/II trial (NCT03389035). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.